Evolva Holding SA (EVE.SW)

Executive Summary

Evolva Holding SA is a Swiss biotechnology company that has undergone significant financial and operational restructuring, including the sale of its core assets and delisting from the SIX Swiss Exchange. Once focused on developing nature-inspired ingredients via synthetic biology and fermentation for flavors, fragrances, health, and pharma, the company now appears to be a shell with minimal ongoing operations. Its only clinical pipeline, a Phase 2 trial for EV-077 in Type 2 diabetes, was terminated in 2012. With an estimated market capitalization of approximately $7 million and no disclosed revenue or active programs, Evolva's future hinges on potential asset sales, mergers, or liquidation. The company's low profile and lack of recent developments suggest high uncertainty for shareholders.

Upcoming Catalysts (preview)

• TBDAnnouncement of reverse merger or acquisition30% success
• TBDSale of remaining intellectual property or assets40% success